- Home
- CRIS vs COCP Comparison
CRIS vs COCP Comparison
Compare CRIS & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | COCP |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 13.5M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRIS | COCP |
|---|---|---|
| Price | $0.90 | $1.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.50 | $6.00 |
| AVG Volume (30 Days) | ★ 1.1M | 85.7K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,650,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $7.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $0.77 | $0.90 |
| 52 Week High | $3.65 | $2.67 |
Technical Indicators
Market Signals| Indicator | CRIS | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 63.19 |
| Support Level | $0.80 | $0.91 |
| Resistance Level | $0.93 | $1.22 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 30.93 | 75.81 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).